Besipirdine (HP 749) reduces schedule-induced polydipsia in rats

Brain Research Bulletin

Volumn 41, Issue 2, 1996, Pages 125-130

  Woods Kettelberger, A T ^a   Smith, C P ^a   Corbett, R ^a   Szewczak, M R ^a   Roehr, J E ^a   Bores, G M ^a   Klein, J T ^a   Kongsamut, Sathapana ^a  

^a SANOFI   (France)

Author keywords

Non selective reuptake inhibitor; Obsessive compulsive disorder; Schedule induced polydipsia

Indexed keywords

BESIPIRDINE; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; SEROTONIN UPTAKE INHIBITOR; TETRABENAZINE;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOGENESIS; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG EFFECT; DRUG INDUCED DISEASE; NONHUMAN; OBSESSION; POLYDIPSIA; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM; SYNAPTOSOME;

EID: 0029792955     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(96)00163-3     Document Type: Article

References (46)

1. 1. Bland, R. C.; Newman, S. C.; Orn, H. Lifetime prevalence of psychiatric disorders in Edmonton. Acta Psychiatr. Scand. 77(Suppl 338):24-32; 1988.
2. 2. Bland, R. C.; Orn, H.; Newman, S. C. Period prevalence of psychiatric disorders in Edmonton. Acta Psychiatr. Scand. 77(Suppl 338):33-42; 1988.
3. 3. Camacho, F.; Vargas, H. M.; Smith, C. P.; Winslow, J. T. Combined cholinergic and adrenergic candidates for Alzheimer's disease (AD) therapy (III): In Vivo efficacy. Soc. Neurosci. Abstr. 21:1975; 1995.
4. 4. Canon, J. G.; Lippa, A. S. Effects of clozapine, chlorpromazine and diazepam upon adjunctive and schedule controlled behaviors. Pharmacol. Biochem. Behav. 6:581-587; 1977.
5. 5. Cornfeldt, M.; Wirtz-Brugger, F.; Szewczak, M.; Blitzer, R.; Landau, E.; Haroutunian, V.; Effland, R.; Klein, J.; Smith, C. HP 749 (I): A pharmacological profile of a therapeutic agent for Alzheimer's disease. Soc. Neurosci. Abstr. 16:612; 1990.
6. 6. De Boer, T.; Nefkens, F.; Van Helvoirt, A. The α2-adrenoceptor antagonist Org 3770 enhances serotonin neurotransmission in vivo. Eur. J. Pharmacol. 253:R5-R6; 1994.
7. 7. Effland, R. C.; Klein, J. T.; Davis, K. L.; Olsen, G. E. N - (Pyridinyl)-1H-indol-1-amines U.S. Patent No. 4,970,218; 1990.
8. 8. Falk, J. L. The nature and determinants of adjunctive behavior. Physiol. Behav. 6:577-588; 1971.
9. 9. Garratt, J. C.; Crespi, F.; Mason, R.; Marsden, C. A. Effects of idazoxan on dorsal raphe 5-hydroxytyrptamine neuronal function. Eur. J. Pharmacol. 193:87-93; 1991.
10. 2-adrenoceptor antagonist with serotonin uptake-blocking activity and putative antidepressant-like effects: II. Pharmacology profile. Drug Dev. Res. 35:246-260; 1995.
11. 11. Goodman, W. K.; Price, L. H.; Delgado, D. L.; Palumbo, J.; Krystal, J. H.; Nagy, L. M.; Rasmussen, S. A.; Heninger, G. R.; Charney, D. S. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Arch. Gen. Pyschiatr. 47:577-585; 1990.
12. 12. Goodman, W. K.; McDougle, C. J.; Price, L. H. Pharmacotherapy of obsessive compulsive disorder. J. Clin. Psychiatr. 53 [suppl. 4]:29-37; 1992.
13. 13. Grebb, J. A.; Jasinsky, O.; Thys, R.; Kennedy, S.; Stramek, J. J.; Cutler, N. R.; Sebree, T.; Kashkin, K. B. (1994) A pilot efficacy stuy of A-75200 in patients with major depressive disorders. Abstr. CINP Regional Workshop "Critical issues in treatment of affective disorders." Paris, France.
14. 14. Hancock, A. A.; Buckner, S. A.; Giardina, W. J.; Brune, M. E.; Lee, J. Y.; Morse, P. A.; Oheim, K. W.; Stanisic, D. S.; Warner, R. B.; Kerkman, D. J.; DeBernardis, J. F. Preclinical pharmacological actions of (+)(1'R*,R*)-3-phenyl-1-[(1',2',3',4'-tetrahydro-5',6'-méthylène-dioxy-1'-naphthaleneyl)methyl] pyrrolidine methane-sulfonate (ABT200), a potential antidepressant agent which inhibits the neuronal uptake of norepinephrine and antagonizes α2-adrenergic receptors. J. Pharmacol. Exp. Ther. 272:1160-1169; 1995.
15. 15. Hubbard, J. W.; Ledinsky, Y.; Aschoff, S. E.; Cornfeldt, M.; Huger, F. P.; Klein, J.; Effland, R. α-adrenergic activity of metabolite 7480 modulates the cardiovascular effect of HP 749 in the conscious rat and dog. Pharmacologist 33:214; 1991.
16. 16. Huger, F. P.; Smith, C. P.; Petko, W. W.; Conway, P. C.; Effland, R. C.; Klein, J. T. HP 749. A potential therapeutic agent for Alzheimer's disease: II. Neurochemical profile Soc. Neurosci. Abstr. 16:612; 1990.
17. 17. Insel, T. R.; Zohar, J.; Benkelfat, C.; Murphy, D. Serotonin in obsessions, compulsions and the control of aggressive impulses. Ann. N.Y. Acad. Sci. 600:574-586; 1990.
18. 18. Jacobs, B. L. An animal behavioral model for studying central serotoninergic synapses. Life Sci. 19:777-786; 1976.
19. 19. Jenike, M. A. (1990) Drug treatment for obsessive compulsive disorder. In: M. A. Jenike, L. Baer, W. E. Minichiello (Eds.), Obsessive-Compulsive Disorders: Theory and Management. Littleton, Mass.: Year Book Medical Publishers Inc.
20. 20. Karno, M.; Golding, J. M.; Sorenson, S. B.; Burnham, M. A. The epidemiology of obsessive-compulsive disorder in five US communities. Arch. Gen. Psychiatr. 45:1094-1099; 1988.
21. 21. Kongsamut, S.; Nachshen, D. A. Measurement of the cytosolic sodium ion concentration in rat brain synaptosomes by a fluororescence method. Biochim. Biophys. Acta 940:241-246; 1988.
22. 22. Kongsamut, S.; Smith, C. P.; Woods, A. T. (1994) Use of N-(Pyridinyl)-1H-indol-1-amines for the Treatment of Obsessive Compulsive Disorder. U.S. Patent No. 5,356,910.
23. 23. Kuribara, H.; Tadokoro, S. Effects of pyschotropic drugs on FI responding and adjunctive drinking in rats. Pharmacol. Biochem. Behav. 13:657-662; 1980.
24. 24. Leonard, H. L.; Swedo, S. E.; Rapoport, J. L.; Koby, E. V.; Lenane, E. V.; Cheslow, D. L.; Hamburger, S. D. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. Arch. Gen. Psychiatr. 52(5 suppl.):58-62; 1989.
25. 25. Middlemiss, D. N.; Fozard, J. R. 8-Hydroxy-2-(di-n-propyl-amino)-tetralin discriminates between subtypes of the 5-HT1 recognition site. Eur. J. Pharmacol. 90:151-153; 1983.
26. 26. Mittleman, G.; Jones, G. H.; Robbins, T. W. Effects of diazepam, FG7142 and Ro-15-1788 on schedule-induced polydipsia and the temporal control of behavior. Psychopharmacol. 94:103-109; 1988.
27. 27. Mongeau, R.; Blier, P.; de Montigny, C. In vivo electrophysiological evidence for the tonic activation by endogenous noradrenaline of α2-adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn-Schmiedeberg's Arch. Pharmacol. 347:266-272; 1993.
28. 28. Mongeau, R.; de Montigny, C.; Blier, P. Effects of long-term alpha-2 adrenergic antagonists and electroconvulsive treatments on the alph-2 adrenoceptors modulating serotonin neurotransmission. J. Pharmacol. Exp. Ther. 26:1152-1159; 1994.
29. 29. Perrone, M. H.; Hamel, L. T.; Ferrari, R. A.; Haubrich, D. R. Napamezole, an alpha-2 receptor antagonist and monoamine uptake inhibitor in vitro. J. Pharmacol. Exp. Ther. 254:471-475; 1990.
30. 30. Perrone, M. H.; Hamel, L. T.; Ferrari, R. A.; Haubrich, D. R. Napamezole, an alpha-2 receptor antagonist and monoamine uptake inhibitor. J. Pharmacol. Exp. Ther. 254:476-483; 1990.
31. 2-arenoceptors. Life Sci. 44:459-467; 1989.
32. 2 adrenoceptor antagonists as antidepressants. Drugs of the Future 10:841-857; 1985.
33. 33. Pitman, R. K. Animal models of compulsive disorder. Biol. Psychiatr. 26:189-198; 1989.
34. 34. Rapoport, J. L. Recent advances in obsessive-compulsive disorder. Neuropsychopharmacol. 5:1-9; 1991.
35. 35. Rasmussen, S. A.; Eisen, J. L. The epidemiology and differential diagnosis of obsessive compulsive disorder. J. Clin. Psychiatr. 53(Suppl.):4-10; 1992.
36. 36. Roehr, J. E.; Woods, A. T.; Corbett, R.; Kongsamut, S. Changes in paroxetine binding in the cerebral cortex of polydipsic rats. Eur. J. Pharmacol. 278:75-78; 1995.
37. 37. Rowland, N.; Antelman, S. M.; Kocan, D. Elevated water intake in rats treated chronically with amphetamine: drinking in excess of need? Appetite 2:51-66; 1981.
38. 38. Ryan, C. N.; Evenden, J. L.; Petterson, M. Effects of busipirone and ipsapirone on schedule induced polydipsia: comparison with 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) and raclopride. Psychopharmacol. 112:34-44; 1993.
39. 39. Sanger, D. J. Schedule-induced drinking of chlordiazepoxide solutions by rats. Pharmacol. Biochem. Behav. 7:1-6; 1977.
40. 40. Sanger, D. J.; Cornfield-Sumner, P. K. Schedule-induced drinking and thirst: a pharmacological analysis. Pharmacol. Biochem. Behav. 10:471-474; 1987.
41. 41. Santucci. A. S.; Haroutunian, V.; Davis, K. L. Pharmacological alleviation of combined cholinergic/noradrenergic lesion-induced memory deficits in rats. Clin. Neuropharmacol 14(Suppl. 1):S1-S8; 1991.
42. 3H]norepinephrine release from rat cortical slices by N-(n-propyl)-N-(4-pyridinyl)-1H-indol-1-amine. Drug Dev. Res. 32:13-18; 1994.
43. 43. Snodgrass, S. H.; Allen, J. D. Effect of dopamine agents on schedule-and deprivation-induced drinking in rats. Pharmacol. Biochem. Behav. 27:463-475; 1987.
44. 44. Sternbach, H. The serotonin syndrome. Am. J. Psychiatr. 148:705-713; 1991.
45. 45. Woods, A. T.; Smith, C. P.; Szewczak, M. R.; Dunn, R. W.; Cornfeldt, M.; Corbett, R. Selective serotonin reuptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder. Psychopharmacol. 112:195-198; 1993.
46. 46. Zaczek, R.; Tinker, W. J.; Logue, A. R.; Cain, G. A.; Teleha, C. A.; Tam, S. W. Effects of linopiridine, HP 749, and glycyl-prolyl-glutamate on transmitter release and uptake. Drug Dev. Res. 29:203-208; 1993.